Is Lipitor affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: SLCO1B1

Used for: High cholesterol, cardiovascular disease prevention

Lipitor (atorvastatin) and other statins share a characteristic side effect: muscle pain, weakness, and (rarely) more serious muscle damage. For years that was chalked up to individual variation, but pharmacogenetics has clarified a big piece of the puzzle. The SLCO1B1 gene encodes the transporter that pulls statins from your blood into liver cells where they do their work. A common variant, SLCO1B1*5, reduces transporter activity, meaning less statin gets into the liver and more stays in circulation (including in muscle tissue, where it causes the statin-associated muscle symptoms most people know as "statin intolerance"). The clinical signal is strongest for simvastatin, but atorvastatin is also affected at higher doses.

What's in Lipitor

atorvastatin affected by SLCO1B1

Affected by SLCO1B1 · CPIC · Strong evidence

Atorvastatin at low to moderate doses (10 to 40 mg) is less affected by SLCO1B1 variation than simvastatin, but the risk of muscle symptoms still rises at 80 mg daily in patients with reduced SLCO1B1 function. CPIC guidelines recommend using a lower statin dose (20 to 40 mg atorvastatin rather than 80) or switching to a statin less dependent on SLCO1B1 (pravastatin, rosuvastatin, pitavastatin) for patients with decreased or poor SLCO1B1 function. The clinical goal is the same (LDL reduction); the path to it just uses a different statin.

Read the full atorvastatin genetics guide →

Atorvastatin phenotype recommendations

Published guidance from CPIC on how atorvastatin should be dosed or substituted based on your SLCO1B1 phenotype.

Phenotype	What it means	Recommendation	Evidence
Increased Function SLCO1B1	Your genetic result suggests you should respond typically to this statin with standard dosing.	CPIC Prescribe desired starting dose and adjust doses of atorvastatin based on disease-specific guidelines.	Strong
Normal Function SLCO1B1	Your genetic result suggests you should respond typically to this statin with standard dosing.	CPIC Prescribe desired starting dose and adjust doses of atorvastatin based on disease-specific guidelines.	Strong
Decreased Function SLCO1B1	Your genetics suggest you may need a lower starting dose to reduce muscle side effects, especially at higher doses.	CPIC Prescribe ≤40 mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for the 40-mg dose. If dose >40 mg is needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus nonstatin guideline-directed medical therapy).	Strong
Possible Decreased Function SLCO1B1	Your genetics suggest you may need a lower starting dose to reduce muscle side effects, especially at higher doses.	CPIC Prescribe ≤40 mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for the 40-mg dose. If dose >40 mg is needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus nonstatin guideline-directed medical therapy).	Strong
Poor Function SLCO1B1	Your genetics suggest you may be at higher risk of muscle side effects; your doctor may use a lower dose or choose a safer alternative.	CPIC Prescribe ≤20 mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20 mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus nonstatin guideline-directed medical therapy).	Strong
Possible Poor Function SLCO1B1	Your genetics suggest you may be at higher risk of muscle side effects; your doctor may use a lower dose or choose a safer alternative.	CPIC Prescribe ≤20 mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20 mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus nonstatin guideline-directed medical therapy).	Strong
Indeterminate SLCO1B1	The impact of your genotype on response to this drug is unknown.	CPIC Initiate therapy with recommended starting dose.	—
Not available SLCO1B1	The impact of your genotype on response to this drug is unknown.	CPIC Initiate therapy with recommended starting dose.	—

Source: CPIC

The gene behind the guidance

SLCO1B1 Solute Carrier Organic Anion Transporter 1B1

SLCO1B1 is the transporter that moves statins into liver cells where they work. A common variant (called *5) reduces transporter function and leaves more statin circulating in the bloodstream and muscle tissue. That's directly linked to statin-associated muscle pain and, rarely, more serious muscle damage.

People with reduced SLCO1B1 function are at higher risk of statin myopathy, especially on simvastatin and high-dose atorvastatin. Dose reduction or switching statin usually resolves it.

See all drugs affected by SLCO1B1 →

Browse the full drug-class: Statins.

What this means for you

If you've tried a statin and stopped because of muscle pain, don't assume all statins are off-limits. SLCO1B1 testing can tell you whether the issue is likely to apply to other statins in the same class. Many patients who can't tolerate simvastatin or high-dose atorvastatin do fine on pravastatin or rosuvastatin, which depend less on SLCO1B1. Cardiovascular risk reduction from statins is well-established, and the alternative to a statin (not treating known dyslipidemia) has real stakes, so finding a tolerable statin is worth the effort.

FAQ

Is SLCO1B1 testing widely available?

Yes. It's a single-gene test offered through most clinical labs and is a standard component of pharmacogenetic panels. Insurance coverage varies; cardiology and preventive medicine practices are increasingly ordering it proactively for patients starting or struggling with statins.

Does SLCO1B1 explain all statin muscle pain?

No, but it's the biggest single genetic contributor known. Other factors include vitamin D deficiency, thyroid dysfunction, concurrent medications that inhibit statin clearance (certain antibiotics, antifungals, and calcium channel blockers), physical activity levels, and the underlying statin dose. SLCO1B1 status is most useful as one piece of the workup, not as a single-test answer.

Are all statins equally affected?

No. Simvastatin is the most SLCO1B1-dependent (highest risk in reduced-function patients), atorvastatin is moderately affected, and pravastatin and rosuvastatin are least affected. Fluvastatin and pitavastatin also have relatively low SLCO1B1 dependence. Switching statins within the class is often the simplest response to a positive SLCO1B1 result in a patient who needs statin therapy.

Find out how your genetics affect Lipitor

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.